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ABSTRACT 
 
Hepatitis B virus (HBV) infection is endemic in Africa.  As many as 98% of black 
Africans are infected during their lives and about 10% (65 million) have chronic 
HBV infection, which is the cause of 70-80% of all hepatocellular carcinoma (HCC) 
cases. Despite this high prevalence of HBV and the high incidence of HCC in 
Africa, relatively few complete HBV genomes from African HCC cases have been 
deposited in international data bases. In order to gain a clearer understanding of 
the role of genetic variants and mutants in the development of HCC, the complete 
genomes of HBV isolated from southern African HCC patients were amplified and 
molecularly characterized. HBV DNA was extracted from the serum forty HBsAg-
positive HCC patients. Twenty six complete genomes were successfully amplified, 
cloned and sequenced from nine HCC patients.  
 
Phylogenetic analyses of the complete genomes and the individual open reading 
frames of HBV isolates from the HCC patients, led to the classification of all the 
isolates within subgenotype A1.  No isolates belonging to subgenotype A2 and 
genotype D were identified, even though these genotypes/subgenotypes have 
been shown to circulate in South Africa. Three patients contained the uncommon 
combination of serological subtype ayw1 in the subgenotype A1 strain. This 
combination has been found previously in South Africa and the Phillipines. 
 
Seventy-eight percent of the patients carried HBV strains with the double basic 
core promoter (BCP) mutation (1762T/1764A), previously shown to reduce HBeAg 
expression. Furthermore, complete genome sequence analysis has revealed a 
complex combination of mutations, which include at least three or five of these 
residues 1753C1762T1764A1766T1768A1809T1812T occurring as the dominant 
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HBV strains isolated from 5/9 HCC patients. These mutations have previously 
been shown to regulate gene expression at various levels, to enhance viral 
replication and simultaneously decrease HBeAg expression.  
 
All five HBV genomes isolated from one patient contained novel complex BCP 
rearrangements, which introduced 2 HNF1 and 1 putative HNF3 transcription 
factor binding sites. These mutations can enhance viral replication and 
simultaneously abolish HBeAg expression at a transcriptional level. Furthermore, 
truncated core proteins would be expressed from 4/5 isolates and none would 
express wild-type HBx. Several mutations were identified in the pre-S/S genes of 
2/5 isolates, which would result in the expression of novel 3’ truncated medium 
surface proteins (MHBst) and large surface proteins (LHBst). The majority of the 
mutations would contribute to hepatocyte pathogenesis and transformation by 
activating cell proliferating pathways. 
 
Two patients also contained rare HBV variants not previously identified in HBV 
strains from southern Africa. These included an HBV splice variant and a poly (dA) 
variant from patient 10 and patient 6, respectively. These variants occurred in 
combination with other isolates within the respective patients.  
 
The envelope genes were characterised in a total of 18 HCC patients, the pre-S 
gene of HBV contained deletions in 72% of the patients. Deletions across pre-
S1/pre-S2, pre-S2 initiation codon mutations with internal deletions, and S gene 
nonsense mutations were prevalent. Mutated envelope proteins have been shown 
to accumulate within the hepatocyte endoplasmic reticulum (ER) and are a 
characteristic histopathological hallmark of HCC known as ground glass 
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hepatocytes. HBV induced ER stress has been shown to dysregulate several cell 
cycle regulatory pathways, which contribute to HCC.  
 
In addition several novel LHBst and MHBst have been described. These potential 
transactivators require further investigation. The HBV mutations described in this 
study have been associated with increased risk for HCC.  
 
Despite the obvious heterogeneity HBV displays within and between patients, 
there are common characteristics shared between the HBV variants which emerge 
during the development of HCC. These include the BCP and pre-C 
(1753C1762T1764A1766T1768A1809T1812T) mutations and the pre-S/S 
mutations. These mutations are able to affect HBV replication and gene 
expression, and may work synergistically to promote liver dysfunction and HCC. 
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